Keywords

• Rosuvastatin Calcium
• CAS : 147098-20-2
• 147098-20-2

Quick Details

• ProName: Rosuvastatin Calcium of CAS 147098-20-...
• CasNo: 147098-20-2
• Molecular Formula: C44h54caf2n6o12s2
• Appearance: white powder
• Application: Animal Pharmaceuticals
• DeliveryTime: within 2-3 day
• PackAge: carton boc
• Port: tianjin/qingdao/shanghai
• ProductionCapacity: 1000000 Kilogram/Month
• Purity: 99%
• Storage: cool and dry
• Transportation: ship,fly
• LimitNum: 1 Gram
• Heavy metal: 1
• Grade: Industrial Grade
• 1: 100

Superiority

Hebei Mojin Biotechnology Co., Ltd,Our business covers more than 30 countries, most of the big customers come from Europe, America and other countries in the world, we can guarantee the quality and price. In recent decades, with the efforts of all employees, we have established many cooperative companies in shandong, henan, guangdong and other places. Our corporate purpose is based on the market, enhance the strength, take the road of scientific and environmental sustainable development, relying on the country. Technology r & d center, increase the investment in r & d, based on the domestic market, expand the international market, manufacturing quality products, sincere service to the society, into a modern, ecological, scientific and technological enterprise world.

Adenosine triphosphate can be used in the disease caused by tissue injury and activity reduction of ecto enzyme , including heart failure, carditis, miocardial infarction, cerebral arteriosclersis, coronary sclerosis, progressive muscular atrophy , cerebral hemorrhage , chronic hepatitis, cirrhosis of liver and hearing handicap, etc.

Details

Product Detailed

Toluenesulfonic Sorafenib is a kind of novel multi-targeted anticancer drug and was first successfully developed by the German pharmaceutical company Bayer. It can simultaneously take effect on both the tumor cell and tumor vasculature. It has a dual anti-tumor effect: not only by blocking the RAF/MEK/ERK-mediated cell signaling pathway for direct inhibition of tumor cell proliferation, but also by inhibiting VEGF and platelet-derived growth factor (PDGF) receptor for blocking tumor angiogenesis and indirectly inhibition of the growth of tumor cells.

The progression-free survival period of sorafenib group is 2-fold as high as the placebo group (5.8 months vs 2.8 months with hazard ratio being 0.51). Compared with placebo treatment, the sorafenib has significantly improved the quality of life of patients. Sorafenib group facilitated a longer survival period than the placebo group with the risk ratio being 0.72, but this difference did not reach statistical significance. Owing to that this was only the result of the interim analysis; therefore, it is necessary to perform the final comparison analysis upon the final analysis of the test.

Product picture 

Packing &shipping&Payment

Payment:T/T,,moneygram
Packaging Details drum
Port:Tianjin
Lead Time :

Advantage
In stock